AZ funded Non-clinical PhD Studentship (Fixed Term) in selective nanoparticle targeting of senescent alveolar epithelium using an alveolar organoid model
University of Cambridge
Closes
Develop nanoparticle delivery of senescence-modulating therapies to lung epithelial cells in a Cambridge–AstraZeneca doctoral project. Research uses human alveolar organoids, engineered carriers and automated screening to evaluate drug selection, delivery and functional responses relevant to pulmonary fibrosis. The four-year studentship begins in October 2027.